Skip to content
HowShorted

Teladoc Health, Inc. short interest in 2025

In 2025, Teladoc Health, Inc.'s disclosed short interest ran from 13.65% of shares outstanding on 15 Jan 2025 to 13.94% on 31 Dec 2025, a change of +0.29 percentage points. The year's high was 15.58% on 14 Mar 2025 and its low 11.75% on 15 Apr 2025, averaging 13.49% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.07 days on 31 Jan 2025. Full history: Teladoc Health, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Teladoc Health, Inc. in 2025

2025 in figures

Start of year
13.65% (15 Jan 2025)
End of year
13.94% (31 Dec 2025)
Change
+0.29 pp
High
15.58% (14 Mar 2025)
Low
11.75% (15 Apr 2025)
Average
13.49%
Highest days to cover
6.07 (31 Jan 2025)
SEC filings marked
9

Every report in 2025

Teladoc Health, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202513.65%5.41
31 Jan 202513.32%6.07
14 Feb 202512.79%1.94
28 Feb 202514.53%1.70results (8-K), 10-K filed
14 Mar 202515.58%3.54
31 Mar 202512.62%4.38
15 Apr 202511.75%3.30
30 Apr 202511.92%4.14results (8-K)
15 May 202512.32%3.6610-Q filed
30 May 202513.14%5.03
13 Jun 202512.29%4.57
30 Jun 202514.01%2.17
15 Jul 202514.06%3.70
31 Jul 202513.59%2.90results (8-K), 10-Q filed
15 Aug 202513.37%3.37
29 Aug 202513.03%4.91
15 Sep 202513.48%5.95
30 Sep 202513.70%3.72
15 Oct 202514.11%2.41
31 Oct 202513.33%2.27results (8-K), results (8-K), 10-Q filed
14 Nov 202514.89%4.02
28 Nov 202514.49%3.82
15 Dec 202513.93%6.07
31 Dec 202513.94%6.07

See also: Teladoc Health, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.